PEGPH20 (pegylated recombinant human hyaluronidase)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PEGPH20 (pegylated recombinant human hyaluronidase), covering 2020-07-13 to 2020-07-13. Get the full timeline:
Most recent: Clinical Trial Update: Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC) [Phase 1, Phase 2]